Health Canada clears Appili Therapeutics’ phase 2 clinical trial evaluating Favipiravir as prophylactic agent against COVID-19 outbreaks
The National Institute on Ageing has estimated that as of May 6, 2020, 82 percent of deaths related to COVID-19 in Canada were associated with long-term care facilities.